2023
Where Are the Children? A Thematic Analysis of State, Territory, and Tribal Organization Comprehensive Cancer Control Plans
Leraas H, Beckhorn C, Washabaugh C, Thamby J, Greenup R, Haines K, Allen L, Tracy E. Where Are the Children? A Thematic Analysis of State, Territory, and Tribal Organization Comprehensive Cancer Control Plans. Journal Of Pediatric Surgery 2023, 59: 129-133. PMID: 37858391, DOI: 10.1016/j.jpedsurg.2023.09.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarbonyl Cyanide m-Chlorophenyl HydrazoneChildDelivery of Health CareHumansNeoplasmsRisk FactorsUnited StatesConceptsComprehensive Cancer Control ProgramPediatric cancer careCancer careChildhood cancerEarly detectionPediatric cancer survivorshipComprehensive cancer control plansDistrict of ColumbiaCancer control programsCancer control plansAdult cancer riskU.S. territoriesTreatment disparitiesPediatric oncologyRisk factorsCancer preventionLevel IVCancer survivorshipCancer riskPediatric cancerChildhood exposureCancerCancer treatmentCareTribal organizationsUsing Crowdfunding Campaigns to Examine Financial Toxicity and Logistical Burdens Facing Families of Children With Wilms Tumor
Leraas H, Moya-Mendez M, Donohue V, Kawano B, Olson L, Sekar A, Robles J, Wagner L, Greenup R, Haines K, Tracy E. Using Crowdfunding Campaigns to Examine Financial Toxicity and Logistical Burdens Facing Families of Children With Wilms Tumor. Journal Of Surgical Research 2023, 291: 640-645. PMID: 37542779, DOI: 10.1016/j.jss.2023.07.005.Peer-Reviewed Original ResearchMultidimensional financial hardship among uninsured and insured young adult patients with metastatic breast cancer
Wheeler S, Spencer J, Manning M, Samuel C, Reeder‐Hayes K, Greenup R, Spees L, Rosenstein D. Multidimensional financial hardship among uninsured and insured young adult patients with metastatic breast cancer. Cancer Medicine 2023, 12: 11930-11940. PMID: 37148550, PMCID: PMC10242847, DOI: 10.1002/cam4.5885.Peer-Reviewed Original Research
2022
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2018
The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)
Fayanju O, Ren Y, Thomas S, Greenup R, Plichta J, Rosenberger L, Tamirisa N, Force J, Boughey J, Hyslop T, Hwang E. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). Annals Of Surgery 2018, 268: 591-601. PMID: 30048319, PMCID: PMC6496955, DOI: 10.1097/sla.0000000000002953.Peer-Reviewed Original ResearchConceptsPathologic complete responseImproved overall survivalNeoadjuvant chemotherapyOverall survivalComplete responseBreast cancerHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusCox proportional hazards modelHormone receptorsNode-positive patientsTriple-negative diseaseKaplan-Meier curvesBreast cancer patientsMultivariate logistic regressionProportional hazards modelAnatomic extentCancer patientsReceptor subtypesClinical significanceHazards modelTumor subtypesPatientsBreastLogistic regressionThe Effect of Hospital Volume on Breast Cancer Mortality
Greenup R, Obeng-Gyasi S, Thomas S, Houck K, Lane W, Blitzblau R, Hyslop T, Hwang E. The Effect of Hospital Volume on Breast Cancer Mortality. Annals Of Surgery 2018, 267: 375-381. PMID: 27893532, PMCID: PMC5994238, DOI: 10.1097/sla.0000000000002095.Peer-Reviewed Original ResearchConceptsHigh-volume centersNational Cancer Data BaseHospital volumeVolume centersBreast cancerHazard ratioImproved survivalStage 0Case volumeMultivariable Cox proportional hazards modelsMultidisciplinary breast cancer treatmentMultivariable Cox proportional hazardsSurgeons National Cancer Data BaseCox proportional hazards modelAnnual hospital volumeLess common cancersUnilateral breast cancerBreast cancer mortalityBreast cancer patientsCubic spline analysisLog-rank testBreast cancer treatmentCox proportional hazardsProportional hazards modelHigher case volume
2017
Breast Cancer after Augmentation
Cho E, Shammas R, Phillips B, Greenup R, Hwang E, Hollenbeck S. Breast Cancer after Augmentation. Plastic & Reconstructive Surgery 2017, 139: 1240e-1249e. PMID: 28538550, DOI: 10.1097/prs.0000000000003342.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBreast ImplantationBreast ImplantsBreast NeoplasmsCohort StudiesFemaleFollow-Up StudiesHumansIncidenceLogistic ModelsMammaplastyMastectomyMiddle AgedMultivariate AnalysisPostoperative ComplicationsReference ValuesRetrospective StudiesRisk AssessmentStatistics, NonparametricSurgical FlapsTime FactorsTreatment OutcomeUnited StatesConceptsPrior augmentationBreast cancer stageBreast cancerSubglandular augmentationCancer stageImplant placementCLINICAL QUESTION/LEVELPreferred reconstructive methodAdvanced breast tumorsTwo-stage implant reconstructionInvasive breast cancerBreast cancer screeningBreast cancer diagnosisUndergoing mastectomySubpectoral implantsDuctal carcinomaTherapeutic mastectomyCancer screeningTreatment recommendationsImplant reconstructionSubpectoral augmentationAuthors' institutionBreast augmentationMastectomyBreast tumors
2015
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ
Worni M, Akushevich I, Greenup R, Sarma D, Ryser M, Myers E, Hwang E. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ. Journal Of The National Cancer Institute 2015, 107: djv263. PMID: 26424776, PMCID: PMC4707192, DOI: 10.1093/jnci/djv263.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleHumansMastectomyMastectomy, Modified RadicalMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioProportional Hazards ModelsRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneSEER ProgramSentinel Lymph Node BiopsySurvival AnalysisTreatment OutcomeUnited StatesConceptsOverall survivalTreatment patternsPre-invasive breast cancerSentinel lymph node biopsyCox proportional hazards regressionLocoregional treatment optionsNational treatment trendsEnd Results registryLymph node biopsyBreast cancer outcomesLong-term outcomesProportional hazards regressionPatient selection biasCochran-Armitage trend testInverse probability weightsDCIS patientsNode biopsyBilateral mastectomyDuctal carcinomaHazards regressionCancer outcomesTreatment optionsBreast cancerTreatment trendsLumpectomy